Clinical evaluation of Chyawanprash as a preventive measure during the COVID-19 pandemic: An open-label, multicentric, randomized, comparative, prospective, and interventional community-based clinical study on healthy individuals

Godatwar, Pawan Kumar; Deshpande, Shailesh; JoshiDeshmukh, Pranita S; Deshpande, Vaishali; Ghungralekar, Raman; Tamoli, Sanjay; Gupta, Arun Kumar; Vedula, Sasibhushan; Rugvedi, Padmanabha; Kumar, Rajiva

doi:10.4103/jism.jism_27_21

Cited by 9 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,20 The beneficial effect of AYUSH prophylactics in the prevention of COVID-19 has been examined through epidemiological studies in the general population and high-risk groups over time. [21][22][23][24][25][26][27] No studies so far, however, have tried to correlate AYUSH prophylactic intake and post-infection disease prognosis.…”

Section: Introductionmentioning

confidence: 99%

Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study

Chaudhary,

Nayak,

Pandey

et al. 2024

Homeopathy

View full text Add to dashboard Cite

Background Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals. Methods This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery. Results Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (n = 1,556) and 56.81% (n = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; p < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; p < 0.001) and 59.8% (95% CI, 37.80 to 74.10; p < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ2 = 9.01; p = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (p = 0.002). Conclusion AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study. Study registration Clinical Trials Registry—India (CTRI/2020/08/027000).

show abstract

Section: Introductionmentioning

confidence: 99%

Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study

Chaudhary,

Nayak,

Pandey

et al. 2024

Homeopathy

View full text Add to dashboard Cite

show abstract

“…The mixture contains several bioactive herbs (with the major ingredient, amla or Indian gooseberry) with broad-spectrum therapeutic potential, including bioactive antioxidants, anti-inflammatory, adaptogenic, cytoprotective, and rejuvenating properties [23]. The efficacy and safety of CP as an immunomodulator have been demonstrated in preclinical trials [25], and its effectiveness in reducing health care resource utilization (HCRU) (ICU use, hospitalization days) and improving quality of life (QoL) (WHO ordinal scale) as an immunomodulator has been demonstrated in high-quality clinical trials [26][27][28]. However, these interventions and their outcomes presented over different settings and durations have shown mixed results.…”

Section: Introductionmentioning

confidence: 99%

An Ayurvedic Medication (Chyawanprash) as a Prophylaxis for Non-Communicable Disease and Communicable Disease: A Protocol for Systematic Review and Meta-Analysis

Sharma,

Kumari,

Sethuraman

et al. 2023

Cureus

View full text Add to dashboard Cite

Globally, non-communicable diseases (NCDs) and communicable diseases (CDs) are on the rise, posing a significant public health threat. A holistic ayurvedic preparation called chyawanprash (CP) has shown positive outcomes in NCDs and CDs. Hence, we aimed to report the outcomes in a systematic manner. To determine the safety, efficacy, healthcare utilization, and quality of life of CP as an optional therapy for NCD and CD management. This systematic review will adhere to PRISMA-P and Cochrane guidelines for methodological considerations. It will evaluate CP efficacy in diverse populations, considering Ayurvedic and non-Ayurvedic comparators. The study design will encompass randomized controlled trials (RCTs) published from 2010 to 2023 in healthcare settings, controlled environments, and communities. We will also analyze primary outcomes related to immunity biomarkers, vital signs, and secondary outcomes such as quality of life. Data sources and search strategy will involve systematic searches in databases such as Cochrane, PubMed, Google Scholar, Web of Science, and Scopus using MeSH terms and Boolean operators. Screening and data extraction will follow a standardized form with four independent reviewers. Quality assessment will use the Cochrane risk of bias tool. The systematic review will provide an exhaustive summary of the effectiveness and safety of CP to address the growing burden of NCDs and CDs. Registration: CRD42023418994.

show abstract

Medicinal Plants Against SARS-CoV/Corona Virus Infections: Ethnopharmacology, Chemistry, Clinical, and Preclinical Studies

Andole

Thumma

Kusuma

et al. 2023

Reference Series in Phytochemistry

View full text Add to dashboard Cite

Clinical evaluation of Chyawanprash as a preventive measure during the COVID-19 pandemic: An open-label, multicentric, randomized, comparative, prospective, and interventional community-based clinical study on healthy individuals

Cited by 9 publications

References 13 publications

Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study

Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study

An Ayurvedic Medication (Chyawanprash) as a Prophylaxis for Non-Communicable Disease and Communicable Disease: A Protocol for Systematic Review and Meta-Analysis

Medicinal Plants Against SARS-CoV/Corona Virus Infections: Ethnopharmacology, Chemistry, Clinical, and Preclinical Studies

Contact Info

Product

Resources

About